Carronade Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centuri Holdings
CTRI
|
+$20.9M |
| 2 |
Telephone and Data Systems
TDS
|
+$20.4M |
| 3 |
Viasat
VSAT
|
+$14.2M |
| 4 |
TLN
Talen Energy Corp
TLN
|
+$6.41M |
| 5 |
The GEO Group
GEO
|
+$4.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EXEEL
Expand Energy Corp Class C Warrants
EXEEL
|
+$43.8M |
| 2 |
American Express Global Business Travel
GBTG
|
+$13.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Utilities | 4.32% |
| 2 | Communication Services | 3.44% |
| 3 | Technology | 1.8% |
| 4 | Healthcare | 1.28% |
| 5 | Consumer Discretionary | 0.78% |
Similar funds
Carronade Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, Carronade Capital Management held 37 positions worth $7.34B, up 70% from $4.33B the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Carronade Capital Management deployed $2.83B of net new capital in Q4 2025, opening 4 new positions and adding to 23 existing holdings. Its largest new stake was Core Scientific: 100,000 shares worth $1.46M.
By sector, the portfolio is most concentrated in Utilities at 4.3% of assets, down from 7% a quarter earlier, followed by Communication Services and Technology.
On the sell side, the most notable exit was Expand Energy Corp Class C Warrants, an estimated $43.8M sold.
- Carronade Capital Management's largest Q4 2025 buy was Core Scientific: 100,000 shares worth $1.46M.
- Carronade Capital Management added most to Centuri Holdings in Q4 2025, an estimated $20.9M increase.
- Carronade Capital Management fully exited Expand Energy Corp Class C Warrants in Q4 2025, selling an estimated $43.8M.
- Carronade Capital Management's ten largest holdings make up 95% of its $7.34B portfolio in Q4 2025.
- Carronade Capital Management opened 4 new positions and closed 6 in Q4 2025.
- Carronade Capital Management's portfolio value rose 70% quarter-over-quarter to $7.34B.
Based on Carronade Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.